Skip to content
AnalystLens

VERTEX PHARMACEUTICALS INC / MA Annual Report, Year Ended Dec 31, 2005

Filing Date
Filed March 16, 2006
Period End
December 31, 2005
Security
VRTX
In the record · 2016–202610-K1110-Q328-K100

VRTX filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 100 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Mar ’17Mar ’17
  2. Leadership change8-K · Apr ’19Apr ’19
  3. Material agreement8-K · Apr ’21Apr ’21
  4. Leadership change8-K · Aug ’25Aug ’25

01—Abstract

Summary

Summary of the 10-K filed March 16, 2006. Cited figures are marked; the original filing is the authoritative source.

Vertex Pharmaceuticals' FY2005 10-K shows a company still in heavy investment mode: net loss widened to $203.4 milliona ($2.28 per share) from $166.2 million in 2004, driven by R&D rising 29% to $248.5 million as the company advances VX-950 (hepatitis C), VX-702 (rheumatoid arthritis) and VX-770 (cystic fibrosis).

Total revenue grew 57% to $160.9 millionb, supported by $32.8 million in Lexiva/Telzir royalties and $128.1 million in collaborative revenue, though roughly 61% of collaborative R&D revenue came from Novartis and Merck programs that conclude in April and June 2006. Management guided to a 2006 net loss of $205-225 million, revenue of $210-235 million and R&D of $350-370 million, and expects cash above $300 million at year-end 2006, which implies a reliance on new collaborations to replace expiring revenue. Balance sheet strength improved materially during 2005.

A $165.4 millionc June equity offering and exchanges of roughly $155 million of convertible notes for about 10.6 million shares cut outstanding debt to about $160 million and lifted stockholders' equity from $35.4 million to $239.2 million. Cash, equivalents and marketable securities were $407.5 million at year-end. Management states this is sufficient for at least 18 months from filing, a horizon that frames the dilution and financing risk investors should weigh against the pipeline's binary clinical outcomes.

The filing also flags several items that bear on the investment case. Pipeline progress was encouraging, with a 28-day Phase II VX-950 trial showing undetectable HCV RNA in all 12 patients, and a VX-702 Phase II RA trial meeting its primary ACR20 endpoint, though with modest effect sizes (40%d vs. 30% placebo).

Restructuring liabilities tied to the unused Kendall Square lease stand at $43.0 million, and FASB 123(R) adoption will add roughly $34 million of stock compensation expense in 2006. Concentration is high: Novartis, GlaxoSmithKline and Merck accounted for 33%, 33% and 15% of 2005 revenue.

02—Key points

Key Highlights

  1. Net loss widened to $203.4M ($2.28/share) in 2005 from $166.2M in 2004, as R&D rose 29% to $248.5M.
  2. Total revenue rose 57% to $160.9M, comprising $32.8M in Lexiva/Telzir royalties and $128.1M in collaborative R&D revenue.
  3. Three partners (Novartis, GSK, Merck) supplied 81% of 2005 revenue, and the Novartis and Merck research terms end in April and June 2006.
  4. 2006 guidance: net loss of $205-225M, revenue of $210-235M, R&D of $350-370M, and year-end cash above $300M.
  5. Balance sheet strengthened: $165.4M equity raise and about $155M of convertible notes exchanged for stock; equity rose to $239.2M and total debt fell to about $160M.
  6. Cash, equivalents and marketable securities of $407.5M, which management says funds operations for at least 18 months.
  7. Lead pipeline: VX-950 (HCV) entering a 200+ patient Phase II in Q2 2006; VX-702 (RA) Phase II met its primary endpoint; VX-770 (CF) IND planned for H1 2006.

03—Questions

Frequently Asked Questions

  1. Is Vertex close to profitability?

    No. The company expects losses to continue beyond 2006 and projects a 2006 net loss of $205-225M. It states it cannot predict when it will become profitable, if at all. Profitability depends on advancing candidates to market or on large milestone and royalty streams.

  2. How much revenue risk is there from collaborator expirations?

    Substantial. The Novartis and Merck research collaborations end in April and June 2006, and together they produced about 61% of 2005 collaborative R&D revenue. Management is counting on new collaborations, including possible VX-950 ex-North America and VX-702 partnerships, to offset the loss, but says these are not assured.

  3. Will Vertex need more capital?

    Management says existing resources fund planned activities for at least 18 months from filing, but it expects to pursue further capital transactions in 2006 and says future equity or debt raises could dilute holders. Remaining 2007 and 2011 convertible notes total about $160M.

  4. What are the main clinical catalysts?

    The 3-month VX-950 Phase II trial in more than 200 HCV patients (planned for Q2 2006), the VX-702 dose-ranging Phase II with methotrexate, the VX-770 first-in-human trial, and the VX-765 psoriasis Phase IIa data. Each carries the risk of failure typical of early-stage drug development.

  5. Does the Kendall Square lease create hidden liabilities?

    It creates a material, estimate-driven liability. Vertex holds a $43.0M restructuring accrual for the portion of the 290,000 sq ft facility it will not occupy, and the figure depends on sublease rates and timing. Management warns that changes in these assumptions could be material.

04—Continue

← View all 10-K filings